thiazole-4-carboximidic acid amide | 18876-78-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: thiazole-4-carboximidic acid amide
• 英文别名: 4-thiazolyl formamidine；Thiazole-4-carboxamidine；1,3-thiazole-4-carboximidamide
• CAS: 18876-78-3
• 化学式: C₄H₅N₃S
• 分子量: 127.17
• InChiKey: GDTDIYWCUMNNPO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  91
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-氰基-2-亚硝基-乙酸乙酯 、 thiazole-4-carboximidic acid amide 生成 4-Amino-2-(4-thiazolyl)-5-nitrosopyrimidin-6-on
  参考文献：
  名称：

  Holland; Jackson; Chaplen, European Journal of Medicinal Chemistry, 1975, vol. 10, # 5, p. 447 - 449

  摘要：

  DOI：

文献信息

• Dihydropyrimidine Compounds and Their Uses in Preparation of Medicaments for Treating and Preventing Antiviral Diseases
  申请人：Li Song

  公开号：US20100087448A1

  公开（公告）日：2010-04-08

  The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof, to a process for preparing the compound of formula (I), and to use of the compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof as a medicament, in particular as a medicament for the treatment and prevention of type B hepatitis.

  本发明涉及一种式（I）的化合物或其药学上可接受的盐或水合物，制备该式（I）化合物的方法，以及将该式（I）的化合物或其药学上可接受的盐或水合物用作药物，特别是用作治疗和预防乙型肝炎的药物。
• Discovery of <i>N</i>-[Bis(4-methoxyphenyl)methyl]-4-hydroxy-2-(pyridazin-3-yl)pyrimidine-5-carboxamide (MK-8617), an Orally Active Pan-Inhibitor of Hypoxia-Inducible Factor Prolyl Hydroxylase 1–3 (HIF PHD1–3) for the Treatment of Anemia
  作者：John S. Debenham、Christina Madsen-Duggan、Matthew J. Clements、Thomas F. Walsh、Jeffrey T. Kuethe、Mikhail Reibarkh、Scott P. Salowe、Lisa M. Sonatore、Richard Hajdu、James A. Milligan、Denise M. Visco、Dan Zhou、Russell B. Lingham、Dominique Stickens、Julie A. DeMartino、Xinchun Tong、Michael Wolff、Jianmei Pang、Randy R. Miller、Edward C. Sherer、Jeffrey J. Hale

  DOI：10.1021/acs.jmedchem.6b01242

  日期：2016.12.22

  The discovery of novel 4-hydroxy-2-(heterocyclic)pyrimidine-5-carboxamide inhibitors of hypoxia-inducible factor (HIF) prolyl hydroxylases (PHD) is described. These are potent, selective, orally bioavailable across several species, and active in stimulating erythropoiesis. Mouse and rat studies showed hematological changes with elevations of plasma EPO and circulating reticulocytes following single

  描述了新型的缺氧诱导因子（HIF）脯氨酰羟化酶（PHD）的4-羟基-2-（杂环）嘧啶-5-羧酰胺抑制剂的发现。这些在多个物种中均有效，选择性，口服生物利用，并在刺激促红细胞生成中起作用。小鼠和大鼠研究表明，单次口服给药后，血浆血浆EPO和循环网织红细胞升高会引起血液学变化，而大鼠连续4天qd po给药后血红蛋白水平升高。优化过程的主要重点是减少早期化合物在较高物种中观察到的长半衰期。这些努力导致了28（MK-8617）的鉴定，该鉴定已用于贫血的人类临床试验。
• Dihydropyrimidine compounds and their uses in preparation of medicaments for treating and preventing antiviral diseases
  申请人：Beijing Molecule Science and Technology Co., Ltd.

  公开号：US08168642B2

  公开（公告）日：2012-05-01

  The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof, to a process for preparing the compound of formula (I), and to use of the compound of formula (I) or a pharmaceutically acceptable salt or hydrate thereof as a medicament, in particular as a medicament for the treatment and prevention of type B hepatitis.

  本发明涉及式（I）的化合物或其药学上可接受的盐或水合物，制备式（I）的化合物的方法，以及将式（I）的化合物或其药学上可接受的盐或水合物用作药物，特别是用作治疗和预防B型肝炎的药物。
• DIHYDROPYRIMIDINE COMPOUNDS AND THEIR USES IN PREPARATION OF MEDICAMENTS FOR TREATING AND PREVENTING ANTIVIRAL DISEASES
  申请人：Beijing Molecule Science and Technology Co., Ltd.

  公开号：EP2039686B1

  公开（公告）日：2012-02-29